OPRX icon

OptimizeRx

8.05 USD
-0.61
7.04%
Updated Apr 1, 3:25 PM EDT
1 day
-7.04%
5 days
-14.45%
1 month
65.30%
3 months
54.51%
6 months
11.81%
Year to date
54.51%
1 year
-29.51%
5 years
-3.48%
10 years
-22.60%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2% more funds holding

Funds holding: 85 [Q3] → 87 (+2) [Q4]

5.86% less ownership

Funds ownership: 67.58% [Q3] → 61.72% (-5.86%) [Q4]

42% less capital invested

Capital invested by funds: $95.6M [Q3] → $55.3M (-$40.3M) [Q4]

87% less call options, than puts

Call options by funds: $75K | Put options by funds: $569K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$6
25%
downside
Avg. target
$7
13%
downside
High target
$8
1%
downside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
JMP Securities
Constantine Davides
30% 1-year accuracy
10 / 33 met price target
1%downside
$8
Market Outperform
Reiterated
6 Feb 2025
RBC Capital
Sean Dodge
31% 1-year accuracy
11 / 35 met price target
25%downside
$6
Sector Perform
Downgraded
8 Jan 2025

Financial journalist opinion

Based on 6 articles about OPRX published over the past 30 days

Positive
Benzinga
2 weeks ago
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
Neutral
Seeking Alpha
2 weeks ago
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
Neutral
GlobeNewsWire
2 weeks ago
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
3 weeks ago
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
Neutral
GlobeNewsWire
3 weeks ago
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
Neutral
GlobeNewsWire
1 month ago
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call.
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
Neutral
GlobeNewsWire
3 months ago
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
Neutral
GlobeNewsWire
4 months ago
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OptimizeRx to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
4 months ago
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Steve Silvestro - President Conference Call Participants Ryan Daniels - William Blair & Company, LLC Sean Dodge - RBC Capital Markets Kyle Bauser - B. Riley Securities David Grossman - Stifel Financial Constantine Davides - Citizens JMP Stephanie Davis - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call.
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™